Skip to search formSkip to main contentSkip to account menu

Zaltrap

National Institutes of Health

Related topics

Related topics

4 relations
4 ML ziv-aflibercept 25 MG/ML Injection [Zaltrap]Zaltrap Injectable Product

Broader (2)

afliberceptziv-aflibercept

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Monitoring Dual VEGF Inhibition in Human Pancreatic Tumor Xenografts With Dynamic Contrast-Enhanced Ultrasound
Background: Association of drugs acting against different antiangiogenic mechanisms may increase therapeutic effect and reduce… 
Review
2017
Review
2017
European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer
On 1 February 2013, a marketing authorisation valid throughout the European Union was issued for aflibercept (Zaltrap) in… 
2013
2013
Zaltrap: A New Option for the Treatment of Patients with Metastatic Colorectal Cancer Resistant to or Progressing After an Oxaliplatin-Containing Regimen
2012
2012
FDA approves aflibercept (Zaltrap) for metastatic colorectal cancer.
The FDA has approved aflibercept (Zaltrap) to be used with the chemotherapy regimen FOLFIRI in the treatment of adults with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)